4 mm or less, however, suture ligation of the caudal short hepatic veins seemed necessary before passing a tape. Conclusion: The retro-hepatic avascular space is 5mm or larger in a majority of specimens examined and the size of the hanging tape should be selected accordingly.
Background: Studies have described the use of indocyanine green (ICG) fluorescence imaging (ICG-FI) for intraoperative identification of liver tumors. However, a critical comparison of ICG-FI with conventional preoperative and intraoperative imaging is lacking. We aim to critically analyze the intraoperative diagnostic utility of ICG-FI in this manner. Methods: This is an IRB-approved prospective study. Patients underwent liver surgery between 2015 and 2017. ICG was administered intravenously 1 day before surgery.The findings on ICG-FI were compared to those on preoperative cross-sectional imaging (POCSI), intraoperative ultrasound (IOUS), and diagnostic laparoscopy (DL) for identification of liver lesions Results: Forty-one patients underwent liver resection (n = 20), laparoscopic microwave ablation (n = 18), and DL (n = 3) for liver metastases (colorectal, n = 18; neuroendocrine, n = 10; other primary, n = 6), cholangiocarcinoma (n = 3), hepatocellular carcinoma (n = 1) and benign lesions (n = 3). 147 lesions (65 superficial [visible on DL] and 82 deep) in total were detected. Of 147 lesions, POCSI identified 76% (n = 112), IOUS identified 93% (n = 136), and ICG-FI identified 44% (n = 65). ICG-FI detection rate was higher superficial (95%, 62/65) than for deep lesions (4%, 3/82). 3% (4/147) of all lesions were seen on ICGF-I, but not on POCSI or IOUS. However, all of these lesions were small and superificial lesions that were apparent on DL. Conclusion: Although ICG-FI allowed detection of small superficial lesions that were not identifiable by POCSI or IOUS, these lesions were apparent on DL even before ICG-FI. Therefore, its utility as an intraoperative diagnostic modality is limited. We believe that rather than a diagnostic tool, it has more potential for a dynamic use in guiding the resection of superficial lesions and delineating segmental/lobar anatomy. Background: There is little evidence between KRAS mutational status and ablation therapy. The aim of this study is to identify if KRAS mutation has any survival effect on patients undergoing liver ablation therapy and liver resection at a single facility. Methods: Three hundred forty one patients with known Kras status underwent liver resection (LR) or ablative therapies (AT) for CRLM between 1999 and 2016. All patients were reviewed by a multidisciplinary conference. Patient demographics, clinical and oncological outcome were analyzed. Kaplan Meier and Cox Proportional Hazard model were used to analyze the outcome. Results: Two hundred fifty six patients underwent LR and 85 patients underwent AT. While 225 patients (66.0%) have KRAS wild type tumor (wtKRAS), 116 patients (34.0%) have mutant KRAS tumor (mutKRAS). MutKras group has worse overall survival (OS) than wtKRAS group (median survival 42 months in mutKRAS, 49.5 months in wtKras; p = 0.02).In mutKRAS group, there were no significant difference in OS between patients with LR and AT (median survival 39.3 months in AT, 42.5 months in LR; p = 0.64) in comparison to wtKRAS group (median survival 35.2 months in AT, 53.6 months in LR; p = 0.01). After controlling KRAS mutational status, the number of liver metastases is an independent risk factor for survival in both wtKRAS and mutKRAS groups on Cox Proportional Hazard model (HR 1.83, 95%CI 1.16e2.98, p = 0.01, HR 1.98, 95%CI 1.10e3.69, p = 0.02). Conclusion: The treatment modality, either liver resection or ablation, has no impact for OS in patients with KRAS mutation.
